Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Autor: Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., Eertwegh, A. J., Krainer, M., Houédé, Nadine, Santos, R., Mahammedi, H., Ng, S., Maio, M., Franke, F. A., Sundar, S., Agarwal, N., Bergman, A. M., Ciuleanu, T. E., Korbenfeld, E., Sengelov, L., Hansen, S., Logothetis, C., Beer, T. M., McHenry, M. B., Gagnier, P., Liu, D., Gerritsen, W. R., Investigators, C. A.

Publikováno v: Kwon, E D, Drake, C G, Scher, H I, Fizazi, K, Bossi, A, van den Eertwegh, A J M, Krainer, M, Houede, N, Santos, R, Mahammedi, H, Ng, S, Maio, M, Franke, F A, Sundar, S, Agarwal, N, Bergman, A M, Ciuleanu, T E, Korbenfeld, E, Sengeløv, L, Hansen, S, Logothetis, C, Beer, T M, McHenry, M B, Gagnier, P, Liu, D, Gerritsen, W R & CA184-043 Investigators 2014, ' Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial ', Lancet Oncology, vol. 15, no. 7, pp. 700-712 . https://doi.org/10.1016/S1470-2045(14)70189-5
Kwon, E D, Drake, C G, Scher, H I, Fizazi, K, Bossi, A, van den Eertwegh, A J M, Krainer, M, Houede, N, Santos, R, Mahammedi, H, Ng, S, Di Maio, M, Franke, F A, Sundar, S, Agarwal, N, Bergman, A M, Ciuleanu, T E, Korbenfeld, E, Sengelov, L, Hansen, S, Logothetis, C, Beer, T M, McHenry, M B, Gagnier, P, Liu, D & Gerritsen, W 2014, ' Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial ', Lancet Oncology, vol. 15, no. 7, pp. 700-712 . https://doi.org/10.1016/S1470-2045(14)70189-5
Lancet Oncology, 15, 7, pp. 700-12
Lancet Oncology, 15(7), 700-712. Lancet Publishing Group
Lancet Oncology
Lancet Oncology, Elsevier, 2014, 15, pp.700--12. ⟨10.1016/S1470-2045(14)70189-5⟩
Lancet Oncology, 15, 700-12

Item does not contain fulltext BACKGROUND: Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. Our aim was to assess the use of ipilimumab after radiotherapy in patients with met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dae77a6261e49be429378a543af39ccf
https://portal.findresearcher.sdu.dk/da/publications/51fb96bf-6495-4c49-9982-4c82cfe12da9

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Introduction of AI Technology for Objective Physical Function Assessment.

Autor: Kouno, Nobuji^1,2,3 (AUTHOR) naoaki.ishiguro@riken.jp, Takahashi, Satoshi^1,2 (AUTHOR) katsuji.takeda@riken.jp, Komatsu, Masaaki^1,2 (AUTHOR) yusakag2@ncc.go.jp, Sakaguchi, Yusuke^1,2,4 (AUTHOR) kfujioka@ncc.go.jp, Ishiguro, Naoaki² (AUTHOR), Takeda, Katsuji² (AUTHOR), Fujioka, Kyoko¹ (AUTHOR), Matsuoka, Ayumu⁵ (AUTHOR) aymatsuo@ncc.go.jp, Fujimori, Maiko⁵ (AUTHOR) mfujimor@ncc.go.jp, Hamamoto, Ryuji^1,2 (AUTHOR) nkouno@ncc.go.jp

Publikováno v: Bioengineering (Basel). Nov2024, Vol. 11 Issue 11, p1154. 15p.